Asunto(s)
Janus Quinasa 2/metabolismo , Mielofibrosis Primaria/diagnóstico , Adulto , Anciano , Biomarcadores/metabolismo , Diagnóstico Precoz , Femenino , Trasplante de Células Madre Hematopoyéticas , Humanos , Janus Quinasa 2/genética , Masculino , Persona de Mediana Edad , Mielofibrosis Primaria/terapia , Reacción en Cadena en Tiempo Real de la Polimerasa/métodos , Recurrencia , Sensibilidad y Especificidad , Factores de TiempoRESUMEN
CONTEXT: - Cytomegalovirus (CMV) can be transmitted by cellular blood products, leading to severe disease in immunosuppressed patients such as neonates and transplant recipients. To mitigate transfusion-transmitted CMV (TT-CMV), "CMV-safe" blood products (leukoreduced and/or CMV-seronegative) are transfused. Attempts to develop practice guidelines for TT-CMV mitigation have been limited by paucity of high-quality clinical trials. OBJECTIVE: - To assess current TT-CMV mitigation strategies across medical institutions for specific at-risk populations. DESIGN: - Supplemental questions regarding TT-CMV and CMV disease mitigation were added to a College of American Pathologists Transfusion Medicine (Comprehensive) Participant Survey in 2015, addressing whether a given institution provided CMV-safe products for 6 at-risk patient populations. RESULTS: - Ninety percent (2712 of 3032) of institutions reported providing universally leukoreduced blood products. Among institutions without universal leukoreduction, 92% (295 of 320) provided leukoreduced products on the basis of clinical criteria. Eighty-three percent (2481 of 3004) of respondents reported having availability of CMV-seronegative products; however, wide variation in policies was reported governing CMV-seronegative product use. Among all respondents, less than 5% reported using CMV prophylaxis and monitoring in high-risk patient groups. Transplant centers reported higher rates of CMV prophylaxis (25% [97 of 394] solid organ) and monitoring (15% [59 of 394] solid organ) for CMV-negative transplant recipients. CONCLUSIONS: - Universal leukoreduction is the primary strategy for mitigating TT-CMV. While most institutions have both CMV-seronegative and leukoreduced blood products available, consensus is lacking on which patients should receive these products. High-quality studies are needed to determine if CMV-seronegative and leukoreduced blood products are needed in high-risk patient populations.
Asunto(s)
Transfusión Sanguínea , Infecciones por Citomegalovirus/prevención & control , Infecciones por Citomegalovirus/transmisión , Reacción a la Transfusión/prevención & control , Anticuerpos Antivirales/sangre , Citaféresis/métodos , Citomegalovirus/inmunología , Infecciones por Citomegalovirus/inmunología , Humanos , Recién Nacido , Patología Clínica , Guías de Práctica Clínica como Asunto , Factores de Riesgo , Sociedades Médicas , Encuestas y Cuestionarios , Trasplante/efectos adversosRESUMEN
BACKGROUND: Expanding the African American (AA) donor pool is critical to sustain transfusion support for sickle cell disease patients. STUDY DESIGN AND METHODS: The aims were to: 1) apply cognitive computing on donation related metrics to develop a predictive model that effectively identifies repeat AA donors, 2) determine whether a single e-mail communication could improve AA donor retention and compare retention results on higher versus lower predictive score donors, and 3) evaluate the effect of e-mail marketing on AA donor retention with culturally versus nonculturally tailored message. RESULTS: Between 2011 and 2012, 30,786 AA donors donated blood at least once on whom predictive repeat donor scores (PRDSs) was generated from donor-related metrics (frequency of donations, duration between donations, age, blood type, and sex). In 2013, 28% (8657/30,786) of 2011 to 2012 donors returned to donate on whom PRDS was validated. Returning blood donors had a higher mean PRDS compared to nonreturning donors (0.649 vs. 0.268; p < 0.001). In the e-mail pilot, high PRDS (≥0.6) compared to low PRDS (<0.6) was associated with 89% higher donor presentation rate (p < 0.001), 20% higher e-mail opening rate (p < 0.001), and, specifically among those who opened the e-mail, 159% higher presentation rate (p < 0.001). Finally, blood donation rate did not differ (p = 0.79) as a function of generic (n = 9312, 1.4%) versus culturally tailored (n = 9326, 1.3%) message. CONCLUSION: Computational algorithms utilizing readily available donor metrics can identify highly committed AA donors and in conjunction with targeted e-mail communication has the potential to increase the efficiency of donor marketing.
Asunto(s)
Algoritmos , Donantes de Sangre/estadística & datos numéricos , Correo Electrónico , Adolescente , Adulto , Negro o Afroamericano , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto JovenAsunto(s)
Trasplante de Células Madre Hematopoyéticas , Leucemia Mieloide Aguda , Modelos Biológicos , Síndromes Mielodisplásicos , Aloinjertos , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Leucemia Mieloide Aguda/mortalidad , Leucemia Mieloide Aguda/terapia , Masculino , Síndromes Mielodisplásicos/mortalidad , Síndromes Mielodisplásicos/terapia , Valor Predictivo de las Pruebas , Estudios Retrospectivos , Tasa de SupervivenciaRESUMEN
CONTEXT: -Substantial variability between different antibody titration methods prompted development and introduction of uniform methods in 2008. OBJECTIVE: -To determine whether uniform methods consistently decrease interlaboratory variation in proficiency testing. DESIGN: -Proficiency testing data for antibody titration between 2009 and 2013 were obtained from the College of American Pathologists. Each laboratory was supplied plasma and red cells to determine anti-A and anti-D antibody titers by their standard method: gel or tube by uniform or other methods at different testing phases (immediate spin and/or room temperature [anti-A], and/or anti-human globulin [AHG: anti-A and anti-D]) with different additives. Interlaboratory variations were compared by analyzing the distribution of titer results by method and phase. RESULTS: -A median of 574 and 1100 responses were reported for anti-A and anti-D antibody titers, respectively, during a 5-year period. The 3 most frequent (median) methods performed for anti-A antibody were uniform tube room temperature (147.5; range, 119-159), uniform tube AHG (143.5; range, 134-150), and other tube AHG (97; range, 82-116); for anti-D antibody, the methods were other tube (451; range, 431-465), uniform tube (404; range, 382-462), and uniform gel (137; range, 121-153). Of the larger reported methods, uniform gel AHG phase for anti-A and anti-D antibodies had the most participants with the same result (mode). For anti-A antibody, 0 of 8 (uniform versus other tube room temperature) and 1 of 8 (uniform versus other tube AHG), and for anti-D antibody, 0 of 8 (uniform versus other tube) and 0 of 8 (uniform versus other gel) proficiency tests showed significant titer variability reduction. CONCLUSION: -Uniform methods harmonize laboratory techniques but rarely reduce interlaboratory titer variance in comparison with other methods.
Asunto(s)
Anticuerpos/análisis , Técnicas de Laboratorio Clínico/normas , Laboratorios/normas , Ensayos de Aptitud de Laboratorios/normas , Sistema del Grupo Sanguíneo ABO/inmunología , American Medical Association , Anticuerpos/sangre , Anticuerpos/inmunología , Técnicas de Laboratorio Clínico/métodos , Técnicas de Laboratorio Clínico/estadística & datos numéricos , Recolección de Datos/métodos , Recolección de Datos/estadística & datos numéricos , Eritrocitos/inmunología , Hematología/métodos , Hematología/normas , Humanos , Laboratorios/estadística & datos numéricos , Patólogos , Patología Clínica/métodos , Patología Clínica/organización & administración , Patología Clínica/normas , Estándares de Referencia , Sistema del Grupo Sanguíneo Rh-Hr/inmunología , Globulina Inmune rho(D)/análisis , Globulina Inmune rho(D)/sangre , Globulina Inmune rho(D)/inmunología , Estados UnidosRESUMEN
BACKGROUND: The coinfusion of haploidentical CD34+ selected peripheral blood stem cell products with umbilical cord blood (UCB) provides early neutrophil recovery, long-term UCB engraftment, and a lower incidence of graft-versus-host disease; however, this complex transplant presents a scheduling challenge for both the cellular therapy laboratory and the clinical team. Cryopreservation of the haploidentical product can facilitate scheduling, but has been previously shown to be associated with infusion reactions and delayed platelet (PLT) engraftment in allogeneic hematopoietic progenitor cell transplant. STUDY DESIGN AND METHODS: To test whether cryopreservation of the CD34+ selected product compromises the graft, we compared neutrophil and PLT engraftment kinetics for patients receiving freshly infused or cryopreserved products. Seventy-two products collected from haploidentical related donors were CD34+ selected and infused in a combined transplant with UCB: 32 were cryopreserved before infusion and 40 were infused fresh. RESULTS: No adverse infusion events were reported in either group and there was no difference in neutrophil and PLT engraftment time between fresh and cryopreserved products. CONCLUSION: Cryopreservation of a CD34+-selected product can be safely used in a combined transplant with UCB and does not affect engraftment time.
Asunto(s)
Antígenos CD34/metabolismo , Transfusión de Componentes Sanguíneos/normas , Conservación de la Sangre , Criopreservación , Sangre Fetal/citología , Células Madre Hematopoyéticas , Adulto , Anciano , Eliminación de Componentes Sanguíneos/métodos , Conservación de la Sangre/efectos adversos , Conservación de la Sangre/métodos , Conservación de la Sangre/normas , Separación Celular/métodos , Criopreservación/métodos , Femenino , Sangre Fetal/metabolismo , Sangre Fetal/trasplante , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Trasplante Homólogo/normasRESUMEN
Dextran 40 is the main component of the solution used to wash or dilute thawed cord blood unit (CBU) products for stem cell transplant. Dextran 40 became unavailable in the United States as of April 2014. Like many other cellular therapy laboratories in the United States, we found ourselves with limited dextran 40 inventory, a growing CBU transplant requirement, and no alternative solution. Since there are no published alternative washing solutions for cryopreserved CBU we had to develop and validate a new solution rapidly. We chose to validate hydroxyethyl starch (HES) due to its similar ability to stabilize red blood cells and reduce sudden changes in osmolality that occur during thawing. For the validation we used 3 CBUs and thawed and washed each unit with both dextran 40- and HES-based solutions; thus, each CBU served as its own control. We observed no significant differences between the two wash solutions for all the monitored variables including cell viability, cell recovery, or potency measured by colony-forming cell assay. Based on this initial validation we began using HES-albumin for CBU washing after our supply was exhausted. Our initial experience with the first 16 CBU transplants after validation indicates safe infusion and preliminary cord engraftment.
Asunto(s)
Trasplante de Células Madre de Sangre del Cordón Umbilical/métodos , Dextranos/provisión & distribución , Células Madre Hematopoyéticas/citología , Derivados de Hidroxietil Almidón , Recuento de Células Sanguíneas , Conservación de la Sangre , Supervivencia Celular , Ácido Cítrico/farmacología , Ensayo de Unidades Formadoras de Colonias , Criopreservación , Dextranos/farmacología , Electrólitos/farmacología , Eritrocitos/efectos de los fármacos , Glucosa/análogos & derivados , Glucosa/farmacología , Supervivencia de Injerto , Células Madre Hematopoyéticas/efectos de los fármacos , Hemólisis/efectos de los fármacos , Humanos , Derivados de Hidroxietil Almidón/farmacología , Soluciones Isotónicas/farmacología , Concentración OsmolarRESUMEN
Lymphomas are the most common hematologic malignancies with approximately 79,000 new cases estimated for 2013 in the USA. Despite improved outcomes, relapse or recurrence remains a common problem with conventional cytotoxic therapy. Recently, many genetic and molecular mechanisms that drive various cellular events like apoptosis, angiogenesis and cell motility have been more clearly delineated. These new findings, coupled with the advent of high-throughput screening technology have led to the discovery of many compounds that can target specific mutations and/or influence deregulated transcription. In this review, we intend to provide a concise overview of genetic and molecular events that drive cellular processes in lymphomas and represent potential therapeutic targets. Additionally, we briefly discuss the prognostic significance of select biological markers.
Asunto(s)
Antineoplásicos/farmacología , Linfoma/genética , Animales , Antineoplásicos/uso terapéutico , Ciclo Celular , Epigénesis Genética , Humanos , Inmunoterapia , Linfoma/diagnóstico , Linfoma/tratamiento farmacológico , Terapia Molecular Dirigida , Mutación , Pronóstico , Transducción de SeñalRESUMEN
Taxanes play an important role in the management of early-stage and advanced-stage breast cancer. Initial studies sought to determine whether there was antitumor activity in patients with metastatic disease, and identify the optimal agent, dose, and schedule. Subsequent studies established a role for both paclitaxel and docetaxel as adjuvant therapy, determined whether they should be administered concurrently or sequentially with other cytotoxic agents, and also determined the optimal agent, dose, and schedule. Taxanes have also been combined with biologic agents, including anti-HER2-directed therapy and antiangiogenic therapy. The aim of this article is to provide a review of pivotal trials evaluating taxane therapy that have informed the current approach for the use of taxanes in early-stage and advanced-stage breast cancer.
Asunto(s)
Antineoplásicos Fitogénicos/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Taxoides/uso terapéutico , Antineoplásicos Fitogénicos/administración & dosificación , Neoplasias de la Mama/patología , Quimioterapia Adyuvante , Ensayos Clínicos como Asunto , Femenino , Humanos , Metástasis de la Neoplasia , Taxoides/administración & dosificaciónRESUMEN
CONTEXT: The 2000 Institute of Medicine report, 'To Err is Human: Building a Safer Health System', focused the medical community on medical error. This focus led to educational initiatives and legislation designed to minimise errors and increase their disclosure. OBJECTIVES: This study aimed to investigate whether increased general awareness about medical error has affected interns' attitudes toward medical error and disclosure by comparing responses to surveys of interns carried out at either end of the last decade. METHODS: Two cohorts of interns for the academic years 1999, 2000 and 2001 (n = 304) and 2008 and 2009 (n = 206) at a university hospital were presented with two hypothetical scenarios involving errors that resulted in, respectively, no permanent harm and an adverse outcome. The interns were questioned regarding their likely responses to error and disclosure. RESULTS: We collected 510 surveys (100% response rate). For both scenarios, the percentage of interns who would be willing to fully disclose their mistakes increased substantially from 1999-2001 to 2008-2009 ('no permanent harm': 38% and 71%, respectively [p < 0.001]; 'adverse outcome': 29% and 55%, respectively [p < 0.001]). About two thirds of fully disclosing interns in both scenarios believed 'the patient's right to full information' to be the primary reason for their disclosure. Fear of litigation in response to error disclosure decreased (70% and 52%, respectively), the percentage of interns who felt that 'medical mistakes are preventable if doctors know enough' decreased (49% and 31%, respectively), belief that competent doctors keep emotions and uncertainties to themselves decreased (51% and 14%, respectively), and agreement with leaving medicine if one (as an intern) caused harm or death decreased (50% and 3%, respectively). Prior training about medical mistakes increased more than four-fold between the cohorts. CONCLUSIONS: This comparison of intern responses to a survey administered at either end of the last decade reveals that there may have been some important changes in interns' intended disclosure practices and attitudes toward medical error.
Asunto(s)
Actitud del Personal de Salud , Internado y Residencia , Errores Médicos/psicología , Estudiantes de Medicina/psicología , Revelación de la Verdad , Adulto , Estudios de Cohortes , Femenino , Humanos , Masculino , Errores Médicos/estadística & datos numéricos , Persona de Mediana Edad , Relaciones Médico-Paciente , Estudiantes de Medicina/estadística & datos numéricos , Encuestas y Cuestionarios , Factores de Tiempo , Adulto JovenRESUMEN
Rhabdomyosarcoma (RMS) is the most common soft-tissue tumor in childhood, but is extremely rare in elderly. We present a rare case of cardiac RMS, which developed 1 year after the diagnosis and management of acute lymphoblastic leukemia in a 68-year-old female. The occurrence of such phenomena is intriguing, especially in an individual without prior history of malignancy at a younger age. Through the review of the existing literature, we attempt to approach the pathogenesis and clinical manifestations of this rare clinical entity.
Asunto(s)
Neoplasias Cardíacas , Neoplasias Primarias Secundarias , Leucemia-Linfoma Linfoblástico de Células Precursoras B , Rabdomiosarcoma , Edad de Inicio , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Diagnóstico Diferencial , Resultado Fatal , Femenino , Neoplasias Cardíacas/diagnóstico , Neoplasias Cardíacas/tratamiento farmacológico , Neoplasias Cardíacas/epidemiología , Neoplasias Cardíacas/patología , Humanos , Neoplasias Primarias Múltiples/diagnóstico , Neoplasias Primarias Múltiples/etiología , Neoplasias Primarias Secundarias/diagnóstico , Neoplasias Primarias Secundarias/tratamiento farmacológico , Neoplasias Primarias Secundarias/etiología , Leucemia-Linfoma Linfoblástico de Células Precursoras B/diagnóstico , Leucemia-Linfoma Linfoblástico de Células Precursoras B/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras B/epidemiología , Leucemia-Linfoma Linfoblástico de Células Precursoras B/patología , Rabdomiosarcoma/diagnóstico , Rabdomiosarcoma/tratamiento farmacológico , Rabdomiosarcoma/epidemiología , Rabdomiosarcoma/patología , Factores de TiempoRESUMEN
Methotrexate is a common agent used in the management of hematological malignancies, but is often associated with the development of diverse central nervous system adverse events, such as seizures. We present a case of seizures after intrathecal administration of methotrexate, during the management of diffuse large B-cell lymphoma. There was complete resolution of the CNS lesions after chemotherapy along with the interval development of diffuse cerebral edema. We hypothesize that tumor lysis is the underlying mechanism of this untoward event, resulting in the corresponding clinical presentation.